PK and Safety of CJ-30059 vs Co-administration of Candesartan and Amlodipine in Healthy Volunteers

Phase 1, randomised, open-label trial of CJ-30059 in hypertension (HTN) (2 arms), sponsored by HK inno.N Corporation. Primary endpoints: Area Under the plasma concentration-time Curve (AUC_last) of Amlodipine up to 72 hours, Area Under the plasma concentration-time Curve (AUC_last) of Candesartan up to 72 hours and 2 more. Status: unknown.